Improving Renal Cell Carcinoma Patient Outcomes with Multi-targeted TKIs and Immune Checkpoint Inhibitors – Live

Description

Program Description

---

Click to Go to the Event Registration

Renal cell carcinoma (RCC) accounts for around 90 percent of kidney cancers. Early-stage renal cancers tend to have a better prognosis, while advanced cancers have a worse prognosis. Historically, approximately 25-30% of patients diagnosed with RCC had metastasis at diagnosis. However, due to the increased use of radiologic and ultrasound imaging techniques, incidental detection is more frequent, and more patients are diagnosed with Stage I–III (localized or loco-regional) disease. Patients with early-stage RCC have a 5-year survival rate of 65%, while metastatic patients have a 5-year survival rate of approximately 12%. People with a strong family history of RCC may have a higher chance of developing it. Certain genetic conditions, including von Hippel-Lindau disease, may also increase the risk of developing RCC.

Agenda

---

• Pretest Clinical Vignette 1 (Audience polling)
• Role of von Hippel-Lindau (VHL) gene mutations and activation of HIF-2α in the treatment of metastatic renal cell carcinoma (mRCC)
• Posttest Clinical Vignette 1 (Audience polling)
• Pretest Clinical Vignette 2 (Audience polling)
• Discuss the combination therapy with checkpoint inhibitors (ICIs) and TKIs for mRCC
• Posttest Clinical Vignette 2 (Audience polling)
• Pretest Clinical Vignette 3 (Audience polling)
• Discuss immune-related adverse-event management of overlapping toxicities of ICIs and TKIs to improve outcomes for patients with mRCC
• Posttest Clinical Vignette 3 (Audience polling)
• Questions from participants and panel discussion

Intended Audience

---

Oncologists, nurse practitioners, physician assistants, and nurses.

Commercial Supporter

---

Supported by an educational grant from Merck Sharp & Dohme and Exelixis, Inc.